Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients

Leukemia

Volumn 19, Issue 12, 2005, Pages 2166-2176

  Colla, S ^a   Morandi, F ^a   Lazzaretti, M ^a   Rizzato, R ^a   Lunghi, P ^a   Bonomini, S ^a   Mancini, C ^a   Pedrazzoni, M ^a   Crugnola, M ^a   Rizzoli, V ^a   Giuliani, Nicola ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Angiogenesis; Bone marrow; Multiple myeloma; Osteopontin

Indexed keywords

GROWTH FACTOR; INTERLEUKIN 6; OSTEOPONTIN; SMALL INTERFERING RNA; SOMATOMEDIN C; SYNDECAN 1; TRANSCRIPTION FACTOR RUNX2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MATRIX; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TUMOR GROWTH;

EID: 28544451084     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403976     Document Type: Article

References (38)

1. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-3073.
2. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003; 45: 227-244.
3. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001; 28: 565-569.
4. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17: 2025-2031.
5. Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003; 101: 2775-2783.
6. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C et al. Pro-angiogenetic properties of human myeloma cells: Production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis. Blood 2003; 102: 638-645.
7. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin - a molecule for all seasons. Q J Med 2002; 95: 3-13.
8. Sato M, Morii E, Komori T, Sato M, Morii E, Komori T et al. Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/ CBFA1 and ETS1 in the skeletal tissues. Oncogene 1998; 17: 1517-1525.
9. Inman CK, Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 2003; 278: 48684-48689.
10. Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003; 63: 2631-2637.
11. Harada H, Tagashira S, Fujiwara M, Ogawa S, Katsumata T, Yamaguchi A et al. Cbfa1 isoforms exert functional differences in osteoblast differentiation. J Biol Chem 1999; 274: 6972-6978.
12. Liu YN, Kang BB, Chen JH. Transcriptional regulation of human osteopontin promoter by C/EBPalpha and AML-1 in metastatic cancer cells. Oncogene 2004; 23: 278-288.
13. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083-1093.
14. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996; 149: 293-305.
15. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994; 74: 214-224.
16. Takahashi F, Akutagawa S, Fukumoto H, Tsukiyama S, Ohe Y, Takahashi K et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 2002; 98: 707-712.
17. Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 2003; 198: 107-117.
18. Rittling SR, Chen Y, Feng F, Wu Y. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem 2002; 277: 9175-9182.
19. Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinegard D, Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metast 2003; 20: 437-444.
20. Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S et al. Enhanced production of osteopontin in multiple myeloma: Clinical and pathogenic implications. Br J Haematol 2003; 123: 263-270.
21. Standal T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT et al, Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 2004; 89: 174-182.
22. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M et al. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res 2001; 29: E21.
23. Helbling D, Mueller BU, Timchenko NA, Hagemeijer A, Jotterand M, Meyer-Monard S et al. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proc Natl Acad Sci USA 2004; 101: 13312-13317.
24. Colla S, Morandi F, Lazzaretti M, Polistena P, Svaldi M, Coser P et al. Do human myeloma cells directly produce basic FGF? Blood 2003; 102: 3071-3072.
25. Angelucci A, Festuccia C, Gravina GL, Muzi P, Bonghi L, Vicentini C et al. Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate 2004; 59: 157-166.
26. Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R et al. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/ PTC-transformed thyroid cells. Oncogene 2004; 23: 2188-2196.
27. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 1994; 54: 832-837.
28. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484-2491.
29. Vincent T, Mechti N. IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia 2004; 18: 967-975.
30. Lin YH, Huang CJ, Chao JR, Chen ST, Lee SF, Yen JJ et al. Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol Cell Biol 2000; 20: 2734-2742.
31. Leali D, Dell'Era P, Stabile H, Sennino B, Chambers AF, Naldini A et al. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol 2003; 171: 1085-1093.
32. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001; 276: 44926-44935.
33. Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL et al. Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997; 90: 1649-1655.
34. Duong LT, Lakkakorpi P, Nakamura I, Rodan GA. Integrins and signaling in osteoclast function. Matrix Biol 2000; 19: 97-105.
35. Karsenty G. Minireview: Transcriptional control of osteoblast differentiation. Endocrinology 2001; 142: 2731-2733.
36. Barille S, Pellat-Deceunynck C, Bataille R, Amiot M. Ectopic secretion of osteocalcin, the major non-collagenous bone protein, by the myeloma cell line NCI-H929. J Bone Miner Res 1996; 11: 466-471.
37. Shui C, Spelsberg TC, Riggs BL, Khosla S. Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res 2003; 18: 213-221.
38. Choi SJ, Oba T, Callander NS, Jelinek DF, Roodman GD. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. Blood 2003; 101: 3778-3783.